Progress on diagnosis and treatment of HPV-related oropharyngeal cancer

doi:10.19438/j.cjoms.2022.06.015

Abstract

Abstract: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been on the rise in recent years, and HPV infection is a critical risk factor for the occurrence of OPSCC. Due to its unique biological characteristics, sensitivity to chemoradiotherapy and good prognosis, HPV-related OPSCC has been classified as an independent disease in the 2017 AJCC and WHO staging system. However, there is no obvious difference in the clinical treatment of patients with HPV-related or non-related OPSCC. Therefore, search for a more suitable treatment plan for patients with HPV-related OPSCC has become a hot spot of current concern. This article reviewed the recent advances in the diagnosis and treatment of HPV-related OPSCC.

Key words: Human papillomavirus, Oropharyngeal cancer, De-intensification strategy, Targeted therapy, Immunotherapy

CLC Number:

R739.8

WU Ya-ping, GAO Jia-min, SUN Shu-yang. Progress on diagnosis and treatment of HPV-related oropharyngeal cancer[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(6): 599-606.

References

[1] Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2] Chaturvedi AK, Engels EA, Pfeiffer RM, et al.Human papillomavirus and rising oropharyngeal cancer incidence in the United States[J]. J Clin Oncol, 2011, 29(32): 4294-4301.
[3] Cogliano V, Baan R, Straif K, et al.Carcinogenicity of human papillomaviruses[J]. Lancet Oncol, 2005, 6(4): 204.
[4] American Joint Committee on Cancer. AJCC Cancer staging manual[M]. 8th Ed. New York: Springer, 2017.
[5] EI-Naggar AK, Chan JKC, Grandis JR, et al.WHO classification of head and neck tumours[M]. Maestro: IARC, 2017.
[6] 尚伟, 郑家伟. 口腔及口咽癌新版TNM分期与NCCN诊治指南部分解读[J]. 中国口腔颌面外科杂志, 2018, 16(6): 533-546.
Shang W, Zheng JW.Interpretation of the new TNM classification and the NCCN guidelines for cancers of the oral cavity and oropharynx[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(6): 533-546.
[7] Bravo IG, Félez-Sánchez M.Papillomaviruses: viral evolution, cancer and evolutionary medicine[J]. Evol Med Public Health, 2015, 2015(1): 32-51.
[8] Kostareli E, Holzinger D, Hess J.New concepts for translational head and neck oncology: lessons from HPV-Related oropharyngeal squamous cell carcinomas[J]. Front Oncol, 2012, 2: 36-45.
[9] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas[J]. Nature, 2015, 517(7536): 576-582.
[10] Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer[J]. J Natl Cancer Inst, 2015, 107(12): djv344.
[11] Näsman A, Du J, Dalianis T.A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine[J]. J Intern Med, 2020, 287(2): 134-152.
[12] Tommasino M.The human papillomavirus family and its role in carcinogenesis[J]. Semin Cancer Biol, 2014, 26: 13-21.
[13] Michaud DS, Langevin SM, Eliot M, et al.High-risk HPV types and head and neck cancer[J]. Int J Cancer, 2014, 135(7): 1653-1661.
[14] Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in3680 patients[J]. J Natl Cancer Inst, 2016, 108(6): djv403.
[15] Liu J, Yang XL, Zhang WS, et al.Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study[J]. Cancer Commun (Lond), 2018, 38(1): 75-83.
[16] Huang H, Zhang B, Chen W, et al.Human papillomavirus infection and prognostic predictors in patients with oropharyngeal squamous cell carcinoma[J]. Asian Pac J Cancer Prev, 2012, 13(3): 891-896.
[17] Xu S, Sun B, Zhou R, et al. Evaluation of p16 as a surrogate marker for transcriptionally active human papillomavirus status of oropharyngeal squamous cell carcinoma in an eastern Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(3): 236-245.e2.
[18] Lam EW, Chan JY, Chan AB, et al.Prevalence, clinicopathological characteristics, and outcome of human papillomavirus-associated oropharyngeal cancer in southern Chinese patients[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 165-173.
[19] Xu T, Shen C, Wei Y, et al.Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): a strong predilection for the tonsil[J]. Cancer Med, 2020, 9(18): 6556-6564.
[20] Cao W, Chen HD, Yu YW, et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[21] Syrjänen K, Syrjänen S, Pyrhänen S.Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas[J]. ORL J Otorhinolaryngol Relat Spec, 1982, 44(6): 323-334.
[22] Haeggblom L, Ramqvist T, Tommasino M, et al.Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years[J]. Papillomavirus Res, 2017, 4: 1-11.
[23] Smeets SJ, Hesselink AT, Speel EJ, et al.A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen[J]. Int J Cancer, 2007, 121(11): 2465-2472.
[24] 中华口腔医学会口腔病理学专业委员会. 口腔癌及口咽癌病理诊断规范[J]. 中国口腔颌面外科杂志, 2020, 18(4): 289-296.
Professional Committee of Oral Pathology, Chinese Stomatological Association. Guideline on pathological diagnosis of oral and oropharyngeal squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(4): 289-296.
[25] Leemans CR, Snijders PJF, Brakenhoff RH.The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282.
[26] Braakhuis BJ, Snijders PJ, Keune WJ, et al.Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus[J]. J Natl Cancer Inst, 2004, 96(13): 998-1006.
[27] Stransky N, Egloff AM, Tward AD, et al.The mutational landscape of head and neck squamous cell carcinoma[J]. Science, 2011, 333(6046): 1157-1160.
[28] Dogan S, Xu B, Middha S, et al.Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx[J]. Int J Cancer, 2019, 145(11): 3152-3162.
[29] Hayes DN, Van Waes C, Seiwert TY.Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors[J]. J Clin Oncol, 2015, 33(29): 3227-3234.
[30] Zhang Y, Koneva LA, Virani S, et al.Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures[J]. Clin Cancer Res, 2016, 22(18): 4735-4745.
[31] Koneva LA, Zhang Y, Virani S, et al.HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers[J]. Mol Cancer Res, 2018, 16(1): 90-102.
[32] Fakhry C, Westra WH, Li S, et al.Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial[J]. J Natl Cancer Inst, 2008, 100(4): 261-269.
[33] Ang KK, Harris J, Wheeler R, et al.Human papillomavirus and survival of patients with oropharyngeal cancer[J]. N Engl J Med, 2010, 363(1): 24-35.
[34] Rischin D, Young RJ, Fisher R, et al.Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(27): 4142-4148.
[35] Gillison ML, Zhang Q, Jordan R, et al.Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer[J]. J Clin Oncol, 2012, 30(17): 2102-2111.
[36] Chaturvedi AK, Graubard BI, Broutian T, et al.Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States[J]. J Clin Oncol, 2018, 36(3): 262-267.
[37] Mehanna H, Bryant TS, Babrah J, et al.Human papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United Kingdom: a cross-sectional study[J]. Clin Infect Dis, 2019, 69(8): 1296-1302.
[38] Licitra L, Perrone F, Bossi P, et al.High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma[J]. J Clin Oncol, 2006, 24(36): 5630-5636.
[39] Nguyen AT, Luu M, Mallen-St Clair J, et al. Comparison of survival after transoral robotic surgery vs nonrobotic surgery in patients with early-stage oropharyngeal squamous cell carcinoma[J]. JAMA Oncol, 2020, 6(10): 1555-1562.
[40] Broglie MA, Stoeckli SJ, Sauter R, et al.Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery[J]. Head Neck, 2017, 39(10): 2004-2015.
[41] Ferris RL, Flamand Y, Weinstein GS, et al.Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311)[J]. J Clin Oncol, 2022, 40(2): 138-149.
[42] Bonner JA, Harari PM, Giralt J, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6): 567-578.
[43] Bonner JA, Harari PM, Giralt J, et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1): 21-28.
[44] Gillison ML, Trotti AM, Harris J, et al.Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50.
[45] Mehanna H, Robinson M, Hartley A, et al.Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial[J]. Lancet, 2019, 393(10166): 51-60.
[46] Kimple RJ, Smith MA, Blitzer GC, et al.Enhanced radiation sensitivity in HPV-positive head and neck cancer[J]. Cancer Res, 2013, 73(15): 4791-800.
[47] Swick AD, Chatterjee A, De Costa AM, et al.Modulation of therapeutic sensitivity by human papillomavirus[J]. Radiother Oncol, 2015, 116(3): 342-345.
[48] Chen AM, Felix C, Wang PC, et al.Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18(6): 803-811.
[49] Misiukiewicz K, Gupta V, Miles BA, et al.Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial[J]. Oral Oncol, 2019, 95: 170-177.
[50] Chera BS, Amdur RJ, Green R, et al.Phase Ⅱ trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. J Clin Oncol, 2019, 37(29): 2661-2669.
[51] Ma DJ, Price KA, Moore EJ, et al.Phase Ⅱ evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma[J]. J Clin Oncol, 2019, 37(22): 1909-1918.
[52] Keysar SB, Astling DP, Anderson RT, et al.A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins[J]. Mol Oncol, 2013, 7(4): 776-790.
[53] Jimeno A, Shirai K, Choi M, et al.A randomized, phase Ⅱ trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer[J]. Ann Oncol, 2015, 26(3): 556-561.
[54] Jimeno A, Bauman JE, Weissman C, et al.A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer[J]. Oral Oncol, 2015, 51(4): 383-388.
[55] Brand TM, Hartmann S, Bhola NE, et al.Cross-talk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer[J]. Cancer Res, 2018, 78(9): 2383-2395.
[56] Dunn LA, Riaz N, Fury MG, et al.A phase 1b study of cetuximab and BYL719 (alpelisib) concurrent with intensity modulated radiation therapy in stage Ⅲ-ⅣB head and neck squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2020, 106(3): 564-570.
[57] Kaneda MM, Messer KS, Ralainirina N, et al.PI3Kgamma is a molecular switch that controls immune suppression[J]. Nature, 2016, 539(7629): 437-442.
[58] De Henau O, Rausch M, Winkler D, et al.Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells[J]. Nature, 2016, 539(7629): 443-447.
[59] Molinolo AA, Hewitt SM, Amornphimoltham P, et al.Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative[J]. Clin Cancer Res, 2007, 13(17): 4964-4973.
[60] Freudlsperger C, Horn D, Weissfuss S, et al.Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma[J]. Int J Cancer, 2015, 136(12): 2775-2785.
[61] Avan A, Narayan R, Giovannetti E, et al.Role of Akt signaling in resistance to DNA-targeted therapy[J]. World J Clin Oncol, 2016, 7(5): 352-369.
[62] Ma BB, Lui VW, Hui CW, et al.Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines[J]. Invest New Drugs, 2013, 31(3): 567-575.
[63] Raymond E, Tourneau CL, Gatineau M, et al.CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC)[J]. AJR Am J Roentgenol, 2013, 177(5): 1041-1044.
[64] Rampias T, Sasaki C, Weinberger P, et al.E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells[J]. J Natl Cancer Inst, 2009, 101(6): 412-423.
[65] Butz K, Ristriani T, Hengstermann A, et al.siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells[J]. Oncogene, 2003, 22(38): 5938-5945.
[66] Wu C, Nilsson K, Zheng Y, et al.Short half-life of HPV16 E6 and E7 mRNAs sensitizes HPV16-positive tonsillar cancer cell line HN26 to DNA-damaging drugs[J]. Int J Cancer, 2019, 144(2): 297-310.
[67] Xu C, Liu W, Hu Y, et al.Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy[J]. Theranostics, 2020, 10(7): 3325-3339.
[68] Jiang Z, Albanese J, Kesterson J, et al.Monoclonal antibodies against human papillomavirus E6 and E7 oncoproteins inhibit tumor growth in experimental cervical cancer[J]. Transl Oncol, 2019, 12(10): 1289-1295.
[69] Jiang P, Wang L, Hou B, et al.A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer[J]. Theranostics, 2018, 8(13): 3544-3558.
[70] Accardi L, Paolini F, Mandarino A, et al.In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16[J]. Int J Cancer, 2014, 134(11): 2742-2747.
[71] Li S, Zhang W, Jiang K, et al.Nanobody against the E7 oncoprotein of human papillomavirus 16[J]. Mol Immunol, 2019, 109: 12-19.
[72] Matheson CJ, Backos DS, Reigan P.Targeting WEE1 kinase in cancer[J]. Trends Pharmacol Sci, 2016, 37(10): 872-881.
[73] Osman AA, Monroe MM, Ortega Alves MV, et al.Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence[J]. Mol Cancer Ther, 2015, 14(2): 608-619.
[74] Moser R, Xu C, Kao M, et al.Functional kinomics identifies candidate therapeutic targets in head and neck cancer[J]. Clin Cancer Res, 2014, 20(16): 4274-4288.
[75] Tanaka N, Patel AA, Wang J, et al.Wee-1 kinase inhibition sensitizes high-risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins[J]. Clin Cancer Res, 2015, 21(21): 4831-4844.
[76] Méndez E, Rodriguez CP, Kao MC, et al.A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2018, 24(12): 2740-2748.
[77] Sridharan V, Margalit DN, Lynch SA, et al.Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer[J]. Br J Cancer, 2016, 115(2): 252-260.
[78] Wood O, Woo J, Seumois G, et al.Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors[J]. Oncotarget, 2016, 7(35): 56781-56797.
[79] Seiwert TY, Burtness B, Mehra R, et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965.
[80] Powell SF, Gold KA, Gitau MM, et al.Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study[J]. J Clin Oncol, 2020, 38(21): 2427-2437.
[81] Harrington KJ, Ferris RL, Blumenschein G Jr, et al.Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(8): 1104-1115.
[82] Ferris RL, Blumenschein G Jr, Fayette J, et al.Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018, 81: 45-51.
[83] Bauml J, Seiwert TY, Pfister DG, et al.Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study[J]. J Clin Oncol, 2017, 35(14): 1542-1549.
[84] Cohen EEW, Soulières D, Le Tourneau C, et al.Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167.
[85] Cillo AR, Kurten CHL, Tabib T, et al.Immune landscape of viral- and carcinogen-driven head and neck cancer[J]. Immunity, 2020, 52(1): 183-199 e9.
[86] Stevanovic S, Helman SR, Wunderlich JR, et al.A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493.
[87] Doran SL, Stevanovic S, Adhikary S, et al.T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2019, 37(30): 2759-2768.
[88] Burki TK.TCR gene therapy for HPV-associated epithelial cancers[J]. Lancet Oncol, 2019, 20(9): e474.
[89] Draper LM, Kwong ML, Gros A, et al.Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6[J]. Clin Cancer Res, 2015, 21(19): 4431-4439.